Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND CVE:GZD CVE:MLY NYSE:NBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$197.24+1.3%$186.31$118.03▼$208.16$11.91B0.39385,346 shs215,170 shsGZDGrizzly DiscoveriesC$0.02+33.3%C$0.02C$0.02▼C$0.03C$3.46M-0.7057560,584 shs80,000 shsMLYMulti-Metal DevelopmentC$0.04+14.3%C$0.04C$0.01▼C$0.06C$10.05M0.49515,689 shs139,000 shsNBYNovaBay Pharmaceuticals$2.19-20.1%$1.23$0.46▼$4.44$12.76M0.622.54 million shs1.15 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.49%-5.17%-1.87%+12.56%+63.24%GZDGrizzly Discoveries0.00%+33.33%+33.33%0.00%-33.33%MLYMulti-Metal Development0.00%0.00%0.00%0.00%0.00%NBYNovaBay Pharmaceuticals+5.79%+1.48%+343.72%+343.22%+476.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$197.24+1.3%$186.31$118.03▼$208.16$11.91B0.39385,346 shs215,170 shsGZDGrizzly DiscoveriesC$0.02+33.3%C$0.02C$0.02▼C$0.03C$3.46M-0.7057560,584 shs80,000 shsMLYMulti-Metal DevelopmentC$0.04+14.3%C$0.04C$0.01▼C$0.06C$10.05M0.49515,689 shs139,000 shsNBYNovaBay Pharmaceuticals$2.19-20.1%$1.23$0.46▼$4.44$12.76M0.622.54 million shs1.15 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.49%-5.17%-1.87%+12.56%+63.24%GZDGrizzly Discoveries0.00%+33.33%+33.33%0.00%-33.33%MLYMulti-Metal Development0.00%0.00%0.00%0.00%0.00%NBYNovaBay Pharmaceuticals+5.79%+1.48%+343.72%+343.22%+476.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$244.3623.89% UpsideGZDGrizzly Discoveries 0.00N/AN/AN/AMLYMulti-Metal Development 0.00N/AN/AN/ANBYNovaBay Pharmaceuticals 3.00Buy$0.85-61.19% DownsideCurrent Analyst Ratings BreakdownLatest GZD, MLY, NBY, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $230.008/19/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$254.00 ➝ $260.008/8/2025ASNDAscendis Pharma A/SCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025ASNDAscendis Pharma A/SWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$289.00 ➝ $295.008/8/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$243.00 ➝ $290.008/8/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$210.00 ➝ $230.008/8/2025ASNDAscendis Pharma A/SUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$306.00 ➝ $307.008/8/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$212.00 ➝ $220.008/8/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$200.00 ➝ $203.008/8/2025ASNDAscendis Pharma A/SStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$212.00 ➝ $254.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M30.68N/AN/A($1.88) per share-104.91GZDGrizzly DiscoveriesN/AN/AC$0.00 per share6.88C$0.06 per shareN/AMLYMulti-Metal DevelopmentN/AN/AC$0.01 per share5.00C$0.16 per shareN/ANBYNovaBay Pharmaceuticals$9.78M1.30N/AN/A$4.25 per share0.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A821.83N/A-54.94%N/A-24.31%11/13/2025 (Estimated)GZDGrizzly Discoveries-C$555.84K-C$0.00N/A∞N/AN/A-5.63%-4.12%N/AMLYMulti-Metal DevelopmentC$1.08MC$0.014.00∞N/AN/A4.08%-3.44%N/ANBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ALatest GZD, MLY, NBY, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AGZDGrizzly DiscoveriesN/A1.16%N/AN/AN/AMLYMulti-Metal DevelopmentN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69GZDGrizzly DiscoveriesN/A0.385.15MLYMulti-Metal Development28.650.060.15NBYNovaBay PharmaceuticalsN/A1.150.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AGZDGrizzly Discoveries0.27%MLYMulti-Metal DevelopmentN/ANBYNovaBay Pharmaceuticals23.25%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%GZDGrizzly Discoveries11.12%MLYMulti-Metal Development0.40%NBYNovaBay Pharmaceuticals0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableGZDGrizzly DiscoveriesN/A172.86 millionN/ANot OptionableMLYMulti-Metal DevelopmentN/A251.28 millionN/ANot OptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableGZD, MLY, NBY, and ASND HeadlinesRecent News About These CompaniesNovaBay Pharma Announces Special Cash DividendAugust 26, 2025 | msn.comNovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per ShareAugust 26, 2025 | finance.yahoo.comWhy Is NovaBay Pharmaceuticals Stock (NBY) Up 60% Today?August 20, 2025 | msn.comNovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarAugust 19, 2025 | globenewswire.comNBY NovaBay Pharmaceuticals, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comNovaBay Pharmaceuticals Inc. Stock Grades | NBY | Barron'sMay 26, 2025 | barrons.comNovaBay Pharmaceuticals approves liquidation planApril 24, 2025 | uk.investing.comNovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Poplar Point Capital Partners Acquires 21,654 SharesApril 16, 2025 | insidertrades.comNovaBay Pharmaceuticals Delays Yearly Report FilingApril 1, 2025 | tipranks.comNovaBay Pharmaceuticals to Hold Special Meeting of StockholdersMarch 7, 2025 | businesswire.comNovaBay fails to gain shareholder approval for dissolutionFebruary 5, 2025 | msn.comNovaBay Pharmaceuticals Inc NBYFebruary 1, 2025 | morningstar.comMNovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's WhyDecember 25, 2024 | zacks.comNovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersDecember 19, 2024 | businesswire.comNovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special MeetingDecember 9, 2024 | businesswire.comNovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024November 22, 2024 | businesswire.comNovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase PriceNovember 6, 2024 | businesswire.comNovaBay Pharmaceuticals To Sell Assets Of Its Avenova Brand - Quick FactsSeptember 21, 2024 | markets.businessinsider.comNBY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NovaBay Pharmaceuticals, Inc.'s Avenova Brand and Business Is Fair to ShareholdersSeptember 20, 2024 | businesswire.comAcumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay PharmaceuticalsSeptember 20, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGZD, MLY, NBY, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$197.24 +2.62 (+1.35%) Closing price 04:00 PM EasternExtended Trading$197.30 +0.05 (+0.03%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Grizzly Discoveries CVE:GZDC$0.02 +0.01 (+33.33%) As of 09/12/2025 11:09 AM EasternGrizzly Discoveries Inc. engages in the acquisition, exploration, and development of precious and base metals properties Canada. The company primarily explores for gold, copper, silver, and cobalt deposits. It holds 100% interests in Greenwood Project covering approximately 180,000 contiguous acres in South-central British Columbia; and the Robocop property comprising of five mineral claims that covers an area of 5,864 acres located in southeastern British Columbia. The company also holds an interest at the Alberta diamond project consisting of two wholly owned claim blocks in the Buffalo Head Hills. In addition, it has an option agreement to acquire a 100% interest in ten mineral claims at the Beaverdell property located in Southeast British Columbia; and a 100% interest for the mineral rights to 761.25 hectares in six mineral claims at Midway-Beaverdell in the Greenwood Mining District. The company was formerly known as Grizzly Diamonds Ltd. and changed its name to Grizzly Discoveries Inc. in January 2010. Grizzly Discoveries Inc. was incorporated in 2002 and is headquartered in Edmonton, Canada.Multi-Metal Development CVE:MLYC$0.04 +0.01 (+14.29%) As of 03/17/2023Multi-Metal Development Ltd., a mineral exploration and development company, focuses on identifying, acquiring, and developing natural resource opportunities in the United States, Austria, and Canada. The company explores for molybdenum, copper, silver, tungsten, zinc, germanium, lead, fluorite, cadmium, and rhenium deposits. Its flagship project comprises the CuMo molybdenum project that consists of 105 unpatented mineral claims located in south-central Idaho, the United States. The company was formerly known as American CuMo Mining Corporation. Multi-Metal Development Ltd. was incorporated in 1971 and is headquartered in Vancouver, Canada.NovaBay Pharmaceuticals NYSE:NBY$2.19 -0.55 (-20.07%) As of 04:00 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
